2021 CMSC Annual Meeting

Go back to the CMSC Education Website
Search

Tag: PharmD

Poster-Disease-modifying Therapy

October 25, 2021

Effect of Age on the Change of Lymphocytes and Immunoglobulins during Treatment with Ocrelizumab or Rituximab for Multiple Sclerosis and Related Disorders

Background: Depletion of B lymphocytes is a known therapeutic strategy for multiple sclerosis (MS) and related disorders. Ocrelizumab (OCR)...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Baseline Characteristics and Adherence Among Multiple Sclerosis Patients Initiating Siponimod in Real World

Background: Siponimod was approved in the United States (US) in March 2019 for patients with relapsing forms of Multiple Sclerosis (MS)....

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Generic Perceptions: Measuring Opinions of Patients with MS Toward Generic Disease Modifying Therapies (DMTs)

Background: In 2018, the MS world received its first true generic DMT, and more generics will become available over the next few years....

Read More →

Poster-Case Reports / Case Series

October 25, 2021

Treatment Resistant Tinea Corporis in Multiple Sclerosis Patients Treated with Ocrelizumab

Background: Tinea corporis is a fungal infection of the skin excluding the face, hands, feet, scalp, nail, or groin. It mostly affects the...

Read More →

Poster-Case Reports / Case Series

October 25, 2021

Multiple Sclerosis in a Patient with Neurofibromatosis Type-1

Background: The association of multiple sclerosis (MS) and neurofibromatosis type 1 (NF1) has been rarely reported. Objectives: To report a...

Read More →
MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US
Facebook-f Twitter Linkedin Youtube

© 2021 CMSC